Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.43 |
| ▸ | MAOA | P21397 | 11/20 | 0.43 |
| ▸ | APP | P05067 | 7/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5050762 | 1.00 | MAOB (0.43) | MAOBMAOAAPPPTPN1 | |
| SCHEMBL5047063 | 0.91 | AKR1C3 (0.42) | MAOBAPP | |
| SCHEMBL5047066 | 0.91 | AKR1C3 (0.42) | MAOBAPP | |
| SCHEMBL5047173 | 0.90 | MAOB (0.43) | MAOBMAOAAPP | |
| SCHEMBL5047177 | 0.90 | MAOB (0.43) | MAOBMAOAAPP | |
| SCHEMBL5047068 | 0.85 | MAOB (0.42) | MAOBMAOAAPP | |
| SCHEMBL5048451 | 0.85 | MAOB (0.42) | MAOBMAOAAPP | |
| SCHEMBL5048453 | 0.85 | MAOB (0.42) | MAOBMAOAAPP | |
| SCHEMBL5047064 | 0.85 | MAOB (0.42) | MAOBMAOAAPP | |
| SCHEMBL5047259 | 0.84 | RARA (0.42) | MAOBMAOAAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | claimed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | claimed |
| US-7326803-B2 | Ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-02-05 | — | — | US | disclosed |
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-07-07 | — | — | US | disclosed |
| EP-1513803-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | Galderma Research & Development, S.N.C. (FR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003101945-A1 | LIGANDS THAT ARE INHIBITORS OF THE RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148670-A1 | Novel ligand inhibitors of the RAR receptors, process for preparing same and therapeutic/cosmetic applications thereof | RARA, RARB, RARG | MAOB 2084/4885MAOA 2011/4885APP 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.